Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

49.76 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Here's Why Biohaven Pharmaceutical Is Soaring Today
Preliminary sales figures for the company's new migraine drug were much better than expected. 
Via The Motley Fool
Exposures Product Safety
Jim Cramer Says People Need To Know About Biohaven
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced... 
Via Benzinga
Biohaven Stock Hits Record High As Migraine Drug Trounces Quarterly Forecasts
Biohaven crushed Wall Street's expectations for second-quarter sales of migraine drug Nurtec on Tuesday, leading BHVN stock to pop. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Biohaven Pharmaceutical: Return On Capital Employed Insights
During Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $43.82 million. Despite a 28.93% in earnings, the company posted a loss of $235.88 million. In Q4, Biohaven... 
Via Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
Biotech Movers During ASCO Week
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval. 
Via Talk Markets
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
From Biohaven Pharmaceuticals
Via Business Wire
Biohaven Pharmaceutical Insights: Return On Capital Employed
In Q1, Biohaven Pharmaceutical (NYSE:BHVN) posted sales of $43.82 million. Earnings were up 28.93%, but Biohaven Pharmaceutical still reported an overall loss of $235.88 million.... 
Via Benzinga
Analyst Ratings for Biohaven Pharma Hldgs
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks
The FDA has approved Biohaven Pharmaceutical Holding Co Ltd’s (NYSE: BHVN) dissolvable, Nurtec ODT (rimegepant), for preventive treatment in people who... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
HC Wainwright & Co. lowered Novavax, Inc. (NASDAQ: NVAX) price target from $317 to $294. Novavax shares fell 1.6% to $136.00 in pre-market trading. Needham cut BigCommerce... 
Via Benzinga
Recap: Biohaven Pharma Q1 Earnings
Shares of Biohaven Pharma Hldgs (NYSE:BHVN) fell 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 24.27% over the... 
Via Benzinga
36 Biggest Movers From Yesterday
Gainers UTime Limited (NASDAQ: UTME) shares jumped 110.7% to close at $82.17 on Wednesday. UTime shares jumped 875% on Tuesday after the company priced its IPO at $4 per share.... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Dow Moves Lower as S&P 500 Eyes New Peak
The major benchmarks are relatively flat at midday, as investors await the latest Federal Open Market Committee (FOMC) meeting minutes. 
Via Talk Markets
Topics Stocks
Exposures US Equities
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers UTime Limited (NASDAQ: UTME) jumped 97.4% to $76.99. UTime shares jumped 875% on Tuesday after the company priced its IPO at $4 per share. XL Fleet Corp. (NASDAQ: XL)... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biohaven Crushes Forecasts; What's Next For Its Blockbuster Hopeful?
Biohaven's pre-announcement for sales of migraine treatment Nurtec ODT crushed Wall Street's expectations Wednesday, leading BHVN stock to surge. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.